Tmunity Therapeutics logo

Tmunity Therapeutics Funding & Investors

Philadelphia, PA

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.

tmunity.com

Total Amount Raised: $230,000,000

Tmunity Therapeutics Funding Rounds

  • Series B

    $75,000,000

    Series B Investors

    Andreessen Horowitz
    Gilead Sciences
    Be The Match BioTherapies
    Westlake Village BioPartners
    BrightEdge Fund
    Penn Medicine Co-Investment Program
  • Series A

    $35,000,000

    Series A Investors

    Gilead Sciences
    Ping An Ventures
    Parker Institute for Cancer Immunotherapy
    Be The Match BioTherapies
    Lilly Asia Ventures
    Kleiner Perkins
    Penn Medicine Co-Investment Program
    University of Pennsylvania (Penn)
  • Series A

    $100,000,000

    Series A Investors

    Ping An Ventures
    Parker Institute for Cancer Immunotherapy
    Gilead Sciences
    Be The Match BioTherapies
    Lilly Asia Ventures
    University of Pennsylvania (Penn)
  • Series Unknown

    $10,000,000

    Series Unknown Investors

    Lilly Asia Ventures
    Penn Medicine Co-Investment Program
  • Seed

    $10,000,000

    Seed Investors

    Parker Institute for Cancer Immunotherapy
    Penn Medicine Co-Investment Program
Funding info provided by Diffbot.